Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:class |
DPP-4 inhibitor
|
| gptkbp:clinical_trial |
NCT00339183
NCT00385366 NCT00420280 |
| gptkbp:contraindication |
hypersensitivity to sitagliptin
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:effective_date |
2006-10-16
|
| gptkbp:formulation |
film-coated tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Januvia
|
| gptkbp:ingredients |
gptkb:sitagliptin
|
| gptkbp:invention |
2022-10-16
|
| gptkbp:manufacturer |
gptkb:Merck_&_Co.
|
| gptkbp:marketed_as |
gptkb:Januvia
|
| gptkbp:pharmacokinetics |
bioavailability 87%
|
| gptkbp:regulatory_compliance |
approved
|
| gptkbp:route_of_administration |
oral
|
| gptkbp:side_effect |
headache
nasopharyngitis upper respiratory tract infection |
| gptkbp:strength |
100 mg
50 mg 25 mg |
| gptkbp:used_for |
type 2 diabetes
|
| gptkbp:bfsParent |
gptkb:Merck_Sharp_&_Dohme_Corp.
gptkb:Merck_&_Co.,_Inc. gptkb:Merck_Research_Laboratories |
| gptkbp:bfsLayer |
6
|